- Home
- KROS vs EYPT Comparison
KROS vs EYPT Comparison
Compare KROS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | EYPT |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 1.5B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KROS | EYPT |
|---|---|---|
| Price | $11.00 | $12.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $22.25 | ★ $31.80 |
| AVG Volume (30 Days) | 434.9K | ★ 1.2M |
| Earning Date | 03-04-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $243,864,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $727.07 | $1,031.72 |
| P/E Ratio | $4.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.12 | $3.91 |
| 52 Week High | $22.55 | $19.11 |
Technical Indicators
Market Signals| Indicator | KROS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 27.21 | 36.03 |
| Support Level | $10.49 | $11.88 |
| Resistance Level | $15.21 | $13.32 |
| Average True Range (ATR) | 0.67 | 0.97 |
| MACD | 0.13 | -0.32 |
| Stochastic Oscillator | 21.08 | 11.68 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.